B.Riley raises Viridian Therapeutics shares target on Phase III THRIVE study - Investing.com
B.Riley raises Viridian Therapeutics' price target to $22.00 following positive Phase III THRIVE study results for VRDN-001 (veligrotug), projecting $500-$700 million in annual sales. Viridian also initiates $150 million stock offering and reports $571.4 million in cash reserves. Analysts predict VRDN-001 could capture 25-35% of Tepezza's market share.
Highlighted Terms
Related News
B.Riley raises Viridian Therapeutics shares target on Phase III THRIVE study - Investing.com
B.Riley raises Viridian Therapeutics' price target to $22.00 following positive Phase III THRIVE study results for VRDN-001 (veligrotug), projecting $500-$700 million in annual sales. Viridian also initiates $150 million stock offering and reports $571.4 million in cash reserves. Analysts predict VRDN-001 could capture 25-35% of Tepezza's market share.